Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

CORRECTED-UPDATE 2-Aspen Pharma may expand infant milk business into Saudi Arabia

Published 09/03/2018, 12:19 pm
© Reuters.  CORRECTED-UPDATE 2-Aspen Pharma may expand infant milk business into Saudi Arabia
AZN
-
APNJ
-

(Corrects third bullet point to say First-half normalised HEPS up 26 pct, not 6)

* Co started test sampling in Middle East markets

* Expects to report on infant milk arm review in 6 mths

* First-half normalised HEPS up 26 pct

* Therapeutic focused brands help to lift HEPS, revenue

By Nqobile Dludla

JOHANNESBURG, March 8 (Reuters) - Aspen Pharmacare APNJ.J is looking to expand its infant milk formula business into Saudi Arabia, its deputy chief executive said after the company reported a 26 percent rise in first-half profit.

Aspen has been strengthening its business in emerging markets following the launch of its Alula infant milk formula brand in China last year, which is the world's biggest consumer of infant milk formula products. infant nutritional business, which supplies a wide range of infant nutritional and children's milk products, has a presence in Australasia, Latin America and Sub-Saharan Africa and a growing presence in China.

"We've started some very small test sampling of the markets in the Middle-East where Saudi Arabia is a particularly attractive market," group deputy chief executive Gus Attridge told Reuters after the company published results on Thursday.

"Saudi Arabia has a reasonable population size and excellent buying power so it's a very wealthy country,"

In January, Aspen said it would review the infant milk formula business with options including a sale to a strategic partner. Attridge said he expected to get a report back on these options within six months. which counts developed Europe as its biggest revenue generator, said normalised headline earnings per share (HEPS) for the six-months ended Dec.31, rose to 872 cents from 692 cents, buoyed by a strong result from therapeutic focused brands and positive performance of the pharmaceutical business in its home market.

HEPS is the main profit gauge in South Africa, which strips out certain one-off items.

Group revenue grew 11 percent to 21.9 billion rand ($1.85 billion) from 19.8 billion rand.

Therapeutic focused brands comprising the Anaesthetics, Thrombosis and High Potency and Cytotoxic portfolios, delivered revenue of 9.9 billion rand, contributing 45 percent of total group revenue.

Sub-Saharan Africa was the primary growth driver in regional pharmaceutical brands, underpinned by the South African business which raised revenue 21 percent.

Aspen's shares were up 2.78 percent to 264.15 rand by 1227 GMT.

"The sales achieved in the first half of the 2018 financial year are expected to be maintained in the second half in spite of the continued supply constraints which will prevent realisation of full potential," Aspen said.

It also said performance in the second half would benefit from the additional rights to the AstraZeneca Anaesthetics AZN.L , which it acquired in October. ($1 = 11.8355 rand)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.